John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Inflammatory Bowel Disease and cancer Volume 25, issue 8, Octobre 2018

  • [1] Beaugerie L, Itzkowitz SH. Cancers complicating Inflammatory Bowel Disease. N Engl J Med 2015 ; 373 : 195.
  • [2] Pasternak B., Svanström H., Schmiegelow K. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177:1296-1305.
  • [3] Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis. Clin Gastroenterol Hepatol 2015 ; 13 : 847-858.e4 ; quiz e48-50.
  • [4] Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014 ; 311 : 2406-13.
  • [5] Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with Inflammatory Bowel Disease. JAMA 2017 ; 318 : 1679-86.
  • [6] Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus : Inflammatory Bowel Disease and malignancies. J Crohns Colitis 2015 ; 9 : 945-65.
  • [7] Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012 ; 143 : 390-399.
  • [8] Bourrier A., Carrat F., Colombel J.-F. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43:252-261.
  • [9] Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 2015 ; 148 : 639-651.e28.
  • [10] Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017 ; 11 : 649-70.
  • [11] Bonovas S., Fiorino G., Lytras T. Systematic review with meta-analysis : use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1179-1192.
  • [12] Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013 ; 145 : 166-175.e8.
  • [13] Palascak-Juif V., Bouvier A.M., Cosnes J. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11:828-832.
  • [14] Weber N.K., Fletcher J.G., Fidler J.L. Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn's disease. Abdom Imaging. 2015;40:1060-1067.
  • [15] Beaugerie L., Carrat F., Nahon S. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol. 2018;16:892-899.
  • [16] Wisniewski A, Fléjou J-F, Siproudhis L, et al. Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis, and risk management perspectives. J Crohns Colitis 2017 ; 11 : 1011-8.
  • [17] Shelton E., Laharie D., Scott F.I. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology. 2016;151:97-109.
  • [18] Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742-747.